Authors
Latest:
Skills Shortage: An Imminent Threat to Life Sciences InnovationIndustry needs to realize the potential that new treatments and technologies hold and put skills at the top of its collective agenda, write Ian Marison and Peter Levison.
Latest:
Specialized Metrics to Properly Assess AI-Pharma StartupsAI-Pharma companies are 100 times as complex as FinTech companies. Methodologies used to assess them should be 100 times as rigorous, writes Margaretta Colangelo.
Latest:
Specialized Metrics to Properly Assess AI-Pharma StartupsAI-Pharma companies are 100 times as complex as FinTech companies. Methodologies used to assess them should be 100 times as rigorous, writes Margaretta Colangelo.
Latest:
A Strategic Approach to Pharma R&D Portfolio PlanningWeighing the benefits of a deeper quantitative review for pharma.
Latest:
A Strategic Approach to Pharma R&D Portfolio PlanningWeighing the benefits of a deeper quantitative review for pharma.
Latest:
Pharma Social Media Profiles: An AnalysisShrujitha Ramanujam outlines Unmetric's analysis of pharma's social media activity on LinkedIn and Facebook.
Latest:
The AI Patient Arc: Past, Present, FutureThe story of how AI is improving all aspects of life science is still being written. But AI’s future impact on patients’ daily health will be informed and influenced by the work being realized today, writes Opinder Bawa.
Latest:
Survey Spotlights the CFO’s Strategic RiseFindings support the belief that today’s pharma finance teams should be engaged across all functional areas, including regulatory, supply chain, manufacturing, and commercial. What does that mean for current and future CFOs in the industry?
Latest:
Planning Ahead with AstraZeneca's Pam ChengA discussion with Pam Cheng, executive vice president of Operations, Technology at AstraZeneca about making the transition into a Fortune 500 C-Suite role and leadership advice for success.
Latest:
Site Payments: Drilling in on Forecast, Budget IssuesRepurposing existing technology to alleviate traditional ‘pain points’ in ensuring clinical investigator payments transparency
Latest:
Bridging the Generational Chasm in OncologyHow engaging with digital influencers holds the key for medical affairs.
Latest:
The Role of Commercial Partners in Sales Strategy DevelopmentGreg Flynn discusses the advantages, challenges and possible future of CCOs and outlines their role in effective sales strategy development.
Latest:
Bridging the Diversity GapDiversity and inclusion shouldn’t be something that companies have to work hard at, writes Chris Coe.
Latest:
Adopting New Technology: Barriers and BreakthroughsPreserving positive ROI amid healthcare’s innovation explosion.
Latest:
Use of High-Efficacy Therapies in MSOpinion remains divided regarding how aggressively MS should be treated. Some neurologists believe in the “treat early, treat aggressively” approach, whilst others prefer to “save” HE therapies until the more traditional platform therapies have failed.
Latest:
IP Analysis Provides Insight to Formulate an Effective Business StrategyCreating an IP portfolio strategy that includes R&D, in-licensing, out-licensing, and mergers and acquisitions can help businesses stay ahead of the competition.
Latest:
Supporting Real-World Data Acquisition Using a Human-Centered Design Strategy Within Specialty PharmacySpecialty pharmacy's role in shifting the existing paradigm from a transactional model to an experiential model in ways that can fuel real-world data acquisition and strategy.
Latest:
Supporting Real-World Data Acquisition Using a Human-Centered Design Strategy Within Specialty PharmacySpecialty pharmacy's role in shifting the existing paradigm from a transactional model to an experiential model in ways that can fuel real-world data acquisition and strategy.
Latest:
Supporting Real-World Data Acquisition Using a Human-Centered Design Strategy Within Specialty PharmacySpecialty pharmacy's role in shifting the existing paradigm from a transactional model to an experiential model in ways that can fuel real-world data acquisition and strategy.
Latest:
Proposed Rebates Rule Raises Tough QuestionsThe decision to eradicate pharma rebates and prompt direct discounts for federal beneficiaries could, if passed, upend the market-what are the critical questions for new products?
Latest:
Clearing Up ‘Clear Evidence’ and Implications for Labeling Post-Merck DecisionIntellectual property attorneys discuss the clarified requirements for when state failure-to-warn claims are pre-empted by FDA regulations after the Supreme Court Merck case.
Latest:
Clearing Up ‘Clear Evidence’ and Implications for Labeling Post-Merck DecisionIntellectual property attorneys discuss the clarified requirements for when state failure-to-warn claims are pre-empted by FDA regulations after the Supreme Court Merck case.
Latest:
Changing Drug Benefit Design & Transparency to Impact Drug PricesRick Kelly and Nisha Desai provide an overview of the “American Patients First” blueprint's four key strategies.
Latest:
Making the Most of Maturing Oncology BrandsA checklist of best practices for mid-life products a few years after launch to help companies with growing oncology portfolios determine not only to see if there’s hidden vitality still left in their aging brands.
Latest:
Making the Most of Maturing Oncology BrandsA checklist of best practices for mid-life products a few years after launch to help companies with growing oncology portfolios determine not only to see if there’s hidden vitality still left in their aging brands.
